Compounds > 1-(4-carboxamidophenyl)-3,3-dimethyltriazene
Page last updated: 2024-12-07

1-(4-carboxamidophenyl)-3,3-dimethyltriazene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(4-carboxamidophenyl)-3,3-dimethyltriazene, also known as **Diazofluorene**, is a chemical compound that has attracted attention in research due to its potential applications in several fields. However, it is important to note that this compound is **not commonly used** and its exact properties and applications are not widely documented.

Here's what we can deduce from its structure and potential use:

**Structure and Properties:**

* **Triazene core:** The core of the molecule is a triazene group, which is known for its reactivity and potential for nitrogen release.
* **Phenyl ring:** The molecule contains a phenyl ring with a carboxamide group attached. This functional group may influence the compound's solubility, reactivity, and potential biological activity.
* **Dimethyl substituents:** The dimethyl groups attached to the triazene nitrogen are likely to influence the compound's stability and reactivity.

**Potential Applications:**

Based on the structure, Diazofluorene could potentially be used as:

* **A reagent in organic synthesis:** The triazene group can act as a nitrogen-releasing agent, potentially making this compound useful for diazo transfer reactions or other reactions involving nitrogen insertion.
* **A precursor for other compounds:** The carboxamide group could be modified or reacted to create a variety of derivatives with different functionalities.
* **A potential drug candidate:** The phenyl ring and carboxamide group could potentially interact with biological targets, but further research is needed to confirm this possibility.

**Importance for Research:**

While Diazofluorene is not currently a widely used compound, its structure and potential applications make it an interesting target for research. Further investigation into its chemical properties, synthesis, and potential biological activity could reveal valuable insights and lead to new applications in chemistry, medicine, and other fields.

**Disclaimer:** This information is provided for educational purposes only and should not be considered medical or professional advice. The use of any chemical compound should be done under the supervision of a qualified professional.

Cross-References

ID SourceID
PubMed CID93163
CHEMBL ID46034
MeSH IDM0111308

Synonyms (29)

Synonym
NCI60_041914
NCIOPEN2_001261
brn 1841908
nsc 86441
benzamide, 4-(3,3-dimethyl-1-triazenyl)-
p-(3,3-dimethyltriazeno)benzamide
1-(4'-karboxylamidophenyl)-3,3-dimethyltriazen [german]
1-(4'-carboxylamidophenyl)-3,3-dimethyltriazine
benzamide, p-(3,3-dimethyltriazeno)-
benzamide, p-(3,3-dimethyl-1-triazeno)-
1-(4-carboxamidophenyl)-3,3-dimethyltriazene
4-(3,3-dimethyl-1-triazenyl)benzamide
p-(3,3-dimethyl-1-triazenyl)benzamide
1-(4'-karboxylamidofenyl)-3,3-dimethyltriazenu [czech]
benzamide, p-(3,3-dimethyl-1-triazenyl)-
cb 10286
1-p-carboxamidophenyl-3,3-dimethyltriazene
nsc-86441
33330-91-5
dm-conh2
nsc86441
CHEMBL46034
1-(4'-karboxylamidophenyl)-3,3-dimethyltriazen
1-(p-carbamoylphenyl)-3,3-dimethyltriazene
1-para-carboxamidophenyl-3,3-dimethyltriazene
1-(4'-karboxylamidofenyl)-3,3-dimethyltriazenu
1-(4-carbamoylphenyl)-3,3-dimethyltriazene
DTXSID60879537
4-(3,3-dime-1-triazino)benzamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The close correspondence of the two QSAR leaves essentially no means for the synthesis of more potent, less toxic triazenes."( Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
Greenberg, N; Hansch, C; Hatheway, GJ; Quinn, FR, 1978)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID19219Partition coefficient (logP)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID115855Antitumor activity is evaluated as the percent increase in lifespan of TLX/5 tumor bearing animals at 200 mg/kg, daily x 51984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID1148443Toxicity in CDF1 mouse assessed as concentration required for producing T/C of 1401978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
AID1134314Antitumor activity against mouse TLX5 cells allografted in CBA/LAC mouse assessed as increase in life span at 25 mg/kg, ip from day 3 to 7 from tumor inoculation relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
AID115856Antitumor activity is evaluated as the percent increase in lifespan of TLX/5 tumor bearing animals at 25 mg/kg, daily x 51984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID132179Maximum increase in life span was measured in B6d2F1 mice after implanting murine leukemia L1210 cells(ic, 10e4 cells) at an intracerebral optimal dose of 160 mg/ (kg day)(qd 1-9)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID126750Compound is evaluated in vitro for percent demethylation by mouse liver microsomes1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID115854Antitumor activity is evaluated as the percent increase in lifespan of TLX/5 tumor bearing animals at 12.5 mg/kg, daily x 51984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID115853Antitumor activity is evaluated as the percent increase in lifespan of TLX/5 tumor bearing animals at 100 mg/kg, daily x 51984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID1132826Octanol-saturated water partition coefficient, log D of the compound1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID109681Compound is evaluated for maximum percentage of (Cmax) increase in life span (ILS) in tumor bearing mice1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID23244Partition coefficient (logP)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID115858Antitumor activity is evaluated as the percent increase in lifespan of TLX/5 tumor bearing animals at 50 mg/kg, daily x 51984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID1134316Antitumor activity against mouse TLX5 cells allografted in CBA/LAC mouse assessed as increase in life span at 50 mg/kg, ip from day 3 to 7 from tumor inoculation relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
AID1132823Distribution coefficient, log P of the compound1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID126870Compound is evaluated in vitro for percent metabolism by mouse liver microsomes1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID1134318Antitumor activity against mouse TLX5 cells allografted in CBA/LAC mouse assessed as increase in life span at 100 mg/kg, ip from day 3 to 7 from tumor inoculation relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
AID132735Percent increase in life span was measured in B6d2F1 mice after implanting B16 melanoma cells(ic) at an intracerebral (ic) optimal dose of 40-80 mg/ (kg day)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID1134321Antitumor activity against mouse TLX5 cells allografted in CBA/LAC mouse assessed as increase in life span at 400 mg/kg, ip from day 3 to 7 from tumor inoculation relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
AID132186Maximum increase in life span was measured in B6d2F1 mice after implanting murine leukemia L1210 cells(ip, 10e5 cells) at an intraperitoneal optimal dose of 39 mg/ (kg day)(qd 1-9)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID1132822Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase of host lifespan1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID132737Percent increase in life span was measured in B6d2F1 mice after implanting murine leukemia Ependymoblastoma cells(ic) at an oral optimal dose of 32 mg/ (kg injection)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID126749Compound is evaluated in vitro for percent dealkylation by mouse liver microsomes1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID1123539Mutagenicity in Salmonella typhimurium strain TA92 assessed as number of bacterial revertants after 2 days by Ames test in presence of rat liver S9 fraction1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity study.
AID115857Antitumor activity is evaluated as the percent increase in lifespan of TLX/5 tumor bearing animals at 400 mg/kg, daily x 51984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID1134320Antitumor activity against mouse TLX5 cells allografted in CBA/LAC mouse assessed as increase in life span at 200 mg/kg, ip from day 3 to 7 from tumor inoculation relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
AID1134328Antitumor activity against mouse TLX5 cells allografted in CBA/LAC mouse assessed as increase in life span at 12.5 mg/kg, ip from day 3 to 7 from tumor inoculation relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-(4-chlorophenyl)-3,3-dimethyltriazene
[no description available]		2.8740
1-(4-carboxyphenyl)-3,3-dimethyltriazene
1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd		2.6530
1-phenyl-3,3-dimethyltriazene
[no description available]		2.6530
1-(4-tolyl)-3,3-dimethyltriazene
[no description available]		2.6530
1-(4-nitrophenyl)-3,3-dimethyltriazene
[no description available]		2.3620
3-methyl-1-phenyltriazene
[no description available]		2.3620
aflatoxin b1
Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.		1.9510aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human metabolite
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.8740dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.8740
Germinoblastoma
[description not available]		02.6530
Experimental Neoplasms
[description not available]		02.3620
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.6530
Benign Neoplasms, Brain
[description not available]		01.9610
Malignant Melanoma
[description not available]		01.9610
Anaplastic Ependymoma
[description not available]		01.9610
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9610
Ependymoma
Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)		01.9610
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9610